EU/3/19/2174

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2174 was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for rasagiline for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
rasagiline
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2174

Sponsor's contact details

TMC Pharma (EU) Limited
The Black Church
St. Mary's Place
Dublin D07 P4AX
Ireland
Tel. +353 76 670 5745
E-mail: info@tmcpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating